Htlv-1 viral factor hbz induces ccr4 to promote t-cell migration and proliferation

Cancer Research

Volumn 76, Issue 17, 2016, Pages 5068-5079

  Sugata, Kenji ^a,b   Yasunaga, Jun Ichirou ^a   Kinosada, Haruka ^a   Mitobe, Yuichi ^a   Furuta, Rie ^a   Mahgoub, Mohamed ^a   Onishi, Chiho ^a   Nakashima, Kazutaka ^c   Ohshima, Koichi ^a,c   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C 021; CD103 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR4 ANTAGONIST; KI 67 ANTIGEN; MACROPHAGE DERIVED CHEMOKINE; PROTEIN HBZ; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; UVOMORULIN; VIRAL PROTEIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; HBZ PROTEIN, HUMAN T-CELL LEUKEMIA VIRUS TYPE I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; HUMAN; HUMAN CELL; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; TRANSCRIPTION INITIATION; VIRUS CARCINOGENESIS; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HTLV-1 INFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; CHEMOTAXIS, LEUKOCYTE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, VIRAL; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, CCR4; RETROVIRIDAE PROTEINS;

EID: 84985930485     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0361     Document Type: Article

References (46)

1. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007;7:270-80.
2. Agace WW. Tissue-tropic effector T cells: Generation and targeting opportunities. Nat Rev Immunol 2006;6:682-92.
3. Yoshie O, Matsushima K. CCR4 and its ligands: From bench to bedside. Int Immunol 2015;27:11-20.
4. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001;194:1541-7.
5. Yuan Q, Bromley SK, Means TK, Jones KJ, Hayashi F, Bhan AK, et al. CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 2007;204:1327-34.
6. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002;99:1505-11.
7. Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K, Hasegawa D, et al. Abnormally high levels of virus-infected IFN-gamma? CCR4 CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE 2009;4:e6517.
8. Yamauchi J, Coler-Reilly A, Sato T, Araya N, Yagishita N, Ando H, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis 2015;211:238-48.
9. Nakayama T, Hieshima K, Arao T, Jin Z, Nagakubo D, Shirakawa AK, et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene 2008;27:3221-32.
10. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 2012;30:837-42.
11. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32:1157-63.
12. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015;125:1883-9.
13. Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, et al. Gainof-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 2014;211:2497-505.
14. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 2015;47:1304-15.
15. Kawahira K. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases. Arch Dermatol Res 1999;291:413-8.
16. Matsuoka M, Green PL. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology 2009;6:71.
17. Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, et al. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2009; 6:19.
18. Satou Y, Yasunaga J, Zhao T, Yoshida M, Miyazato P, Takai K, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog 2011;7:e1001274.
19. Zhao T, Satou Y, Sugata K, Miyazato P, Green PL, Imamura T, et al. HTLV-1 bZIP factor enhances TGF-{beta} signaling through p300 coactivator. Blood 2011;118:1865-76.
20. Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, et al. HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression. PLoS Pathog 2013;9:e1003630.
21. Mitagami Y, Yasunaga J, Kinosada H, Ohshima K, Matsuoka M. Interferongamma promotes inflammation and development of T-Cell Lymphoma in HTLV-1 bZIP factor transgenic mice. PLoS Pathog 2015;11:e1005120.
22. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006;103:720-5.
23. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987;70:1069-72.
24. Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, et al. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement. J Exp Med 1985; 162:2169-74.
25. Yokoyama K, Ishikawa N, Igarashi S, Kawano N, Masuda N, Hamaguchi W, et al. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg Med Chem 2009;17:64-73.
26. Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, et al. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009;113:2755-64.
27. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013;110:17945-50.
28. Mitobe Y, Yasunaga J, Furuta R, Matsuoka M. HTLV-1 bZIP factor RNA and protein impart distinct functions on T-cell proliferation and survival. Cancer Res 2015;75:4143-52.
29. Yasuma K, Yasunaga J, Takemoto K, Sugata K, Mitobe Y, Takenouchi N, et al. HTLV-1 bZIP factor impairs anti-viral immunity by inducing coinhibitory molecule, T cell immunoglobulin and ITIM domain (TIGIT). PLoS Pathog 2016;12:e1005372.
30. Sundrud MS, Grill SM, Ni D, Nagata K, Alkan SS, Subramaniam A, et al. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J Immunol 2003;171:3542-9.
31. Lefebvre JS, Marleau S, Milot V, Levesque T, Picard S, Flamand N, et al. Tolllike receptor ligands induce polymorphonuclear leukocyte migration: Key roles for leukotriene B4 and platelet-activating factor. FASEB J 2010; 24:637-47.
32. Sather BD, Treuting P, Perdue N, Miazgowicz M, Fontenot JD, Rudensky AY, et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007;204:1335-47.
33. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26.
34. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-31.
35. Kutlesa S, Wessels JT, Speiser A, Steiert I, Muller CA, Klein G. E-cadherinmediated interactions of thymic epithelial cells with CD103? thymocytes lead to enhanced thymocyte cell proliferation. J Cell Sci 2002; 115:4505-15.
36. O'Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 2008;409:635-49.
37. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
38. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, et al. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002; 62:2971-5.
39. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: Viral infectivity, Tax, HBZ and therapy. Oncogene 2011;30:1379-89.
40. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, Bito T, et al. IFNgamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol 2002; 14:767-73.
41. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64:2127-33.
42. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012;4:117ra7.
43. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996;59:81-9.
44. Wornle M, Schmid H, Merkle M, Banas B. Effects of chemokines on proliferation and apoptosis of human mesangial cells. BMC Nephrol 2004;5:8.
45. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008;122:769-76.
46. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol 2011;12:485-91.